We studied the effect of early antihypertensive treatment on death, major disability, and vascular events among patients with acute ischemic stroke according to their baseline SBP.
INTRODUCTION

S
troke is the second most common cause of death and the leading cause of major, long-term disability worldwide [1] . Prospective cohort studies and clinical trials have demonstrated that hypertension is the most important modifiable risk factor for incident and recurrent stroke [2 -5] . Elevated blood pressure (BP) is common in the acute phase of ischemic stroke, occurring in about 75% of all patients [6] . This increase in BP may be because of uncontrolled or undiagnosed chronic hypertension, or a response to physical and psychological stresses from brain ischemia [7, 8] . This initial hypertensive response is self-limiting and typically resolves over several days, with BP spontaneously declining in most patients [7, 8] . Recently, several clinical trials have shown that individual antihypertensive medications or BPlowering strategies in patients with acute ischemic stroke have a neutral effect on death or major disability outcomes [9] [10] [11] [12] .
Observational epidemiologic studies have reported 'Ushaped' or 'J-shaped' associations of admission BP with subsequent mortality, major disability, and recurrent stroke among patients with acute ischemic stroke [13] [14] [15] . Extreme high BP is clearly detrimental, because it leads to hypertensive encephalopathy, hemorrhagic transformation, cardiac complications, and renal insufficiency [16] . However, an optimal BP range in acute ischemic stroke is still not known. Current clinical guidelines recommend that antihypertensive medications should be withheld unless the SBP is greater than 220 mmHg or the DBP is greater than 120 mmHg among patients with acute ischemic stroke [16] . It is common in clinical practice, nevertheless, to lower BP among patients with acute ischemic stroke if SBP is greater than 180 mmHg [17] .
The China Antihypertensive Trail in Acute Ischemic Stroke (CATIS) was a multicenter randomized controlled trial designed to test the effect of BP reduction within the first 48 h after the onset of an acute ischemic stroke on death and major disability [10] . CATIS provides an opportunity to assess the effect of early antihypertensive treatment on death, major disability, recurrent stroke, and vascular events among patients with acute ischemic stroke according to their baseline SBP levels (<160, 160-179, and !180 mmHg).
METHODS
Trial design and participants
CATIS was a multicenter, single-blind, blinded end-points randomized controlled clinical trial performed in 26 hospitals across China. Details on the trial design and methods have been described in a previous article [10] . In brief, 4071 patients aged 22 years or older who had an acute ischemic stroke within 48 h of symptom onset and an elevated SBP between 140 mmHg and less than 220 mmHg were recruited. Ischemic stroke was confirmed by either computed tomography or magnetic resonance imaging of the brain. Patients who had a SBP at least 220 mmHg, DBP at least 120 mmHg, severe heart failure, acute myocardial infarction, unstable angina, atrial fibrillation, aortic dissection, cerebrovascular stenosis, or resistant hypertension were excluded. Additionally, those in a deep coma and those treated with intravenous thrombolytic therapy were excluded.
This study was approved by the institutional review boards at Tulane University in the United States and Soochow University in China, in addition to the ethical committees at all 26 participating hospitals. Written consent was obtained from all study participants or their immediate family members. A data and safety monitoring board met annually to review the accumulating data for safety and to monitor the trial for either superiority or inferiority of BP reduction on the clinical outcomes.
Intervention
In the CATIS study, patients were randomly assigned to either a control or treatment group. Randomization was conducted centrally and the study population was stratified by hospital and use of hypertension medications. Randomization schedules were generated using SAS PROC PLAN and concealed until an eligible participant was ready for enrollment. Although treating study physicians and nurses were not blinded to group assignments, the patients and research staff who collected study outcome data were masked to treatment allocation.
The treatment group received antihypertensive treatment aimed at lowering SBP by 10-25% within the first 24 h after randomization, reducing SBP to 140 mmHg or less and DBP to 90 mmHg within 7 days, and maintaining this level of BP control for the rest of the patient's hospitalization. The treatment was designed to test for BP strategy rather than the efficacy of individual antihypertensive drugs. As such, multiple antihypertensive agents, including intravenous angiotensin-converting enzyme inhibitors (enalapril, first-line), calcium channel blockers (secondline), and diuretics (third-line), were used individually or in combination to achieve the targeted BP reduction according to a prespecified treatment algorithm that was detailed in a previous article [10] .
At the patient's hospital discharge, trial participants in both groups were prescribed to antihypertensive medications according to clinical guidelines [10] .
Measurements
Participant demographic characteristics and medical histories were collected at enrollment. Stroke severity was assessed using the National Institutes of Health Stroke Scale (NIHSS; scores range from 0 to 42, with higher scores indicating more severe neurologic deficits) at baseline, 14 days or hospital discharge, and 3 months after treatment [18] . Computed tomography or MRI of the brain was performed according to standard techniques to confirm the diagnosis of ischemic stroke in all trial participants. Three BP measurements were obtained at baseline by trained nurses according to a common protocol adapted from procedures recommended by the American Heart Association, and the average of the measurements was used for analysis [19] . BP was measured with the patient in a supine position using a standard mercury sphygmomanometer and one of four cuff sizes (pediatric, regular adult, large adult, or thigh) based on participant's arm circumference. After randomization, three BP measurements were obtained every 2 h for the first 24 h, every 4 h during the second and third days, and three times a day thereafter until hospital discharge or death.
Outcome assessment
The primary outcome was a combination of death and major disability, defined as a modified Ranking Scale score of 3-6 (modified Ranking Scale scores range from 0 to 6, with a score of 0 indicating no symptoms, a score of 5 indicating severe disability, and a score of 6 indicating death) [20] . Secondary outcomes included an ordered seven-level categorical score of the modified Rankin Scale for neurological functional status, vascular disease events (e.g. vascular deaths, nonfatal stroke, nonfatal myocardial infarction, and hospitalized and treated angina, heart failure, or peripheral arterial disease), recurrent fatal and nonfatal stroke, and all-cause mortality assessed at the 3-month posttreatment follow-up visit.
Study outcomes were assessed at 14 days or at hospital discharge, whichever was first, and at 3 months posttreatment by trained neurologists and nurses who were unaware of treatment assignment. Data on medical history, deaths, vascular events, BP, NIHSS score, and modified Rankin Scale score were obtained. Death certificates were obtained for deceased participants. Hospital data was abstracted for all vascular events. A trial-wide outcome assessment committee, blinded to treatment assignment, reviewed, and adjudicated vascular events based on the criteria established in the Antihypertensive and lipid-Lowering Treatment to prevent Heart Attack Trial (ALLHAT) [21] .
Statistical analysis
Data were analyzed according to participants' randomized treatment assignments, regardless of their subsequent medication status (intention-to-treat). Participants were divided into three prespecified subgroups according to their baseline SBP (<160, 160-179, and !180 mmHg). Within each BP subgroup, the proportion of participants with primary and secondary outcomes at 14 days or discharge and at the 3-month posttreatment follow-up visit were compared based on their treatment group using a x 2 -test at a two-sided a level of 5% without correction for multiple comparisons because the subgroup analysis was used to generate study hypotheses rather than test a hypothesis. The medians and interquartile range of Rankin score and hospitalization were calculated and compared using the Wilcoxon rank-sum test [22] . Logistic regression analysis was used to estimate unadjusted odds ratios and 95% confidence intervals associated with comparing treatment groups. Additionally, the odd ratios of ordinal Rankin scores were computed using ordinal logistic regression in order to estimate the effect of BP reduction on the full range of the modified Rankin Scale [23] . Heterogeneity of the treatment effect on primary and secondary outcomes according to BP subgroups was assessed by adding an interaction term in logistic regression models. In a sensitivity analysis, age, sex, baseline SBP, BMI, diabetes, cigarette smoking, stroke subtype, and NIHSS score at baseline as well as time from onset to randomization were adjusted. These prognostic variables were selected as confounders because they were significantly or borderline-significantly different (P < 0.10) between treatment and control groups by baseline BP or they were reported to influence study outcomes [24, 25] . Data analyses were performed using SAS version 9.4 (SAS Institute Inc; Cary, North Carolina, USA) and Stata version 12 (StataCorp; College Station, Texas, USA).
RESULTS
Study participants
Of the 4071 patients included in this study, 2038 were randomly assigned to receive antihypertensive treatment and 2033 were assigned to control. Seven participants in the treatment group and six in the control group withdrew from the trial during hospitalization. In addition, 43 participants in treatment and 40 in control groups were lost to follow-up at 3 months (Fig. 1 ). All participants were included in analysis at 14 days or hospital discharge and 3975 (1988 in intervention and 1987 in control) participants were included in analysis at 3 months.
At baseline there were 1486 patients (719 in the treatment group and 767 in control) in the SBP 160 mmHg or less subgroup, 1696 (841 in treatment and 855 in control) in the SBP 160-179 mmHg subgroup, and 889 (478 in treatment and 411 in control) in the SBP at least 180 mmHg subgroup. Baseline characteristics were balanced between antihypertensive treatment and control comparison in each of the SBP subgroups (Table 1 ).
Blood pressure reduction
At 24 h after randomization, mean SBP was reduced by 12.9 (8.5%), 22.2 (13.2%), and 34.8 mmHg (18.1%) in the treatment group, and 4.1 (2.7%), 13.6 (8.1%), and 27 mmHg (13.9%) in the control group (P < 0.001 for all group differences between treatment and control) for patients with a baseline SBP less than 160, 160-179, and at least 180 mmHg, respectively (Fig. 2) . Mean SBP was 133.2, 137.3, and 143.2 mmHg in the treatment group and 142.5, 147.5, and 152.3 mmHg in the control group at day 7 after randomization (P < 0.001 for all group differences between treatment and control) for patients with a baseline SBP 160 mmHg or less, 160-179 mmHg, and at least 180 mmHg, respectively. The corresponding SBP was 132.5, 135, and 139 mmHg in the treatment group and 140.2, 144.9, and 147.5 mmHg in the control group at day 14 or hospital discharge (P < 0.001 for all group differences between treatment and control), respectively.
Clinical outcomes at 14 days or hospital discharge
At 14 days or hospital discharge, the proportion of patients that experienced the primary outcomes of death or major disability was not significantly different between treatment and control groups based on SBP subgroups (Table 2) . Likewise, there was no significant difference in modified Rankin scale scores between treatment and control among SBP subgroups. However, there was a significant interaction between antihypertensive treatment and baseline SBP subgroups on death (P ¼ 0.02): odds ratio (95% CI) of 2.42 (0.74-7.89) in patients with baseline SBP 160 mmHg or less and 0.34 (0.11-1.09) in patients with baseline SBP !180 mmHg.
Clinical outcomes at 3-month posttreatment follow-up visit
At the 3-month posttreatment follow-up visit, SBP and DBP was significantly lower in the treatment group compared with the control group, with SBP differences (95% CI) of À2.6 (À3.8 to À1.5), À3.3 (À4.5 to À2.1), and À3.4 (À5.2 to À1.6) and DBP differences (95% CI) of À1.6 (À2.4 to À0.8), À1.5 (À2.3 to À0.8) and À1.1 (À2.2 to 0.0) among patients with baseline SBP less than 160, 160-179, and at least 180 mmHg, respectively ( Table 3 ). The proportion of participants who experienced death or major disability was not significantly different between the treatment and control groups among SBP subgroups (Table 3) . Similarly, there was no significant difference in modified Rankin scale scores, recurrent stroke, vascular events, or composite event of vascular events and death between the treatment and control groups by SBP subgroups.
Sensitivity analysis
After adjustment for important prognostic variables, the effects of treatment on clinical outcomes were consistent with the results from unadjusted analyses (Table 4) . Primary outcome (death or major disability) and ordinal modified Rankin score were not significantly different between the treatment and control groups by baseline SBP at both 14 days or hospital discharge and 3 months. However, allcause mortality was significantly reduced in patients with baseline SBP at least 180 mmHg and nonsignificantly increased in patients with baseline SBP less than 180 mmHg (P ¼ 0.01 for interaction). Recurrent stroke, vascular events, and the composite outcome of death and vascular events at 3 months were not significantly different between the treatment and control groups by baseline SBP.
DISCUSSION
The current subgroup analysis of the CATIS trial found no significant difference in stroke adverse outcomes between early antihypertensive treatment and discontinued antihypertensive medications during hospitalization among acute ischemic stroke patients with various SBP levels at baseline. However, this analysis also observed an interaction between antihypertensive treatment and baseline SBP on death and suggested a greater reduction in case-fatality rate during hospitalization among patients with a SBP at least 180 mmHg at baseline.
These study findings may have important clinical significance. Although current clinical guidelines recommend that antihypertensive medications should be withheld unless SBP is greater than 220 mmHg or DBP is greater than 120 mmHg, it is common to lower BP when SBP is greater than 180 mmHg in clinical practice [16, 17] . The findings from this analysis indicate that there was no statistically significant difference in the composite primary outcome of death or major disability between the treatment and control groups among patients with a SBP between 180 and 220 mmHg. Therefore, antihypertensive treatment should be up to the discretion of healthcare providers based on individual clinical judgment as long as the patients have SBP less than 220 mmHg.
Although the most prospective cohort analyses reported U-shaped associations between BP during the acute phase and adverse clinical outcomes in patients with ischemic stroke, extremely elevated BP was consistently associated with worse clinical outcomes [13] [14] [15] [26] [27] [28] [29] . In 17 398 patients with confirmed ischemic stroke from the International Stroke Trial, early death increased by 17.9% for every 10 mmHg fall in SBP among patients with a SBP less than 150 mmHg (P < 0.0001) and increased by 3.8% for every 10 mmHg increase in SBP among patients with a SBP greater than 150 mmHg (P ¼ 0.016) [13] . Among 1874 patients with first-ever acute ischemic stroke from the Fukuoka Stroke Registry, SBP at admission at least 166 mmHg was associated with neurological deterioration (odds ratio 1.92; 95% CI 1.15-3.27) and poor functional outcome (odds ratio 2.51, 95% CI 1.69-3.74) [28] . The current subgroup analyses of the CATIS trial did not show a reduced mortality or disability related to antihypertensive treatment among acute ischemic stroke patients with a SBP 160-180 mmHg, or even at least 180 mmHg. Observational studies might be biased by confounding factors, such as severity of stroke, and underlying mechanisms of BP increase during acute phase of ischemic stroke [30] .
Our study suggested a greater reduction of in-hospital mortality associated with early antihypertensive treatment among acute ischemic stroke patients with a baseline SBP 180-220 mmHg. In the Efficacy of Nitric Oxide in Stroke (ENOS) trial, a suggestive beneficial effect of glyceryl trinitrate on functional outcome at 90 days was observed only among acute ischemic stroke patients with a SBP at least 200 mmHg (odds ratio 0.74, 95% CI 0.48-1.15) [11] . These findings warrant future randomized clinical trials to test the effect of antihypertensive treatment among acute ischemic stroke patients with a SBP 180-220 mmHg at admission.
The mean time from onset to randomization was 15.3 h (SD ¼ 12.9) in the treatment group and 14.9 h (SD ¼ 13.0) in the control group in the CATIS trial [10] . Time from stroke onset to initiation of antihypertensive treatment has been associated with clinical outcomes in patients with acute ischemic stroke [24, 31] .
As a subgroup analysis of a clinical trial, this study had some limitations, such as multiple comparisons, loss of statistical power, and difficulty in interpretation [32] . For example, interactions between antihypertensive treatment and baseline BP have been tested on multiple primary and secondary study outcomes. Therefore, chance or confounding factors could explain the subgroup study findings. However, the study findings did not change after adjusting for important observed prognostic variables. Rather than testing predefined hypotheses, this subgroup analysis has generated study hypotheses for future clinical trials. Additionally, our study participants were exclusively Chinese stroke patients and findings from our study might not be generalizable to other populations in whom the management of acute ischemic stroke might be different. Furthermore, our trial did not compare the appropriate BP treatment targets, times of starting treatment, and classes of antihypertensive drug for early BP lowering in patients with acute ischemic stroke. Finally, cerebral blood flow data were not collected in the CATIS trial. Future trials should collect these data to guide BP management in acute ischemic stroke.
In conclusion, this subgroup analysis of the CATIS trial indicates that early antihypertensive treatment had a neutral effect on clinical outcomes among acute ischemic stroke patients with various levels of SBP at baseline. Future trials are warranted to test early BP-lowering effects in acute ischemic stroke patients by baseline SBP levels. Difference in means between the antihypertensive treatment and control groups was tested using a Student's t-test, percentages using a x 2 -test, and medians using the Wilcoxon ranksum test. IQR, interquartile range. a Scores range from 0 (normal neurologic status) to 42 (coma with quadriplegia). Difference in the percentages of composite death or major disability and all-cause mortality between the antihypertensive treatment and control groups was tested using a x 2 -test, the medians of Rankin score and hospitalization using the Wilcoxon rank-sum test, and odds ratios of ordinal Rankin scores using ordinal logistic regression. OR, odds ratio.
a Modified Rankin Score of 3 or greater.
b Scores on the modified Rankin Scale, for which a score of 0 indicates no symptoms, a score of 5 indicates severe disability, and a score of 6 indicates death.
c
Odds of a 1-unit higher modified Rankin score. Difference in mean blood pressure between the antihypertensive treatment and control groups was tested using a Student's t-test, the percentages of composite death or major disability, all-cause mortality, recurrent stroke, vascular events, and use of antihypertensive medication using a x 2 -test, the medians of Rankin score using the Wilcoxon rank-sum test, and odds ratios of ordinal Rankin scores using ordinal logistic regression. BP, blood pressure; CI, confidence interval; OR, odds ratio.
Odds of a 1-unit higher modified Rankin score. 
